The U.S. Food and Drug Administration (FDA) updated the label for Metformin Hydrochloride Tablets USP on 2025-12-26. This revision clarifies the indication and usage for the drug, specifically stating its role as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus.
Background
Metformin Hydrochloride is a well-established medication used in the management of type 2 diabetes mellitus. The updated label provides a precise statement of its indications and usage. It specifies that Metformin Hydrochloride Tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus.
What this means
This label revision provides clear and updated guidance for healthcare professionals regarding the appropriate use of Metformin Hydrochloride Tablets USP. By explicitly stating its indication as an adjunct to diet and exercise for glycemic control in both adult and pediatric patients with type 2 diabetes mellitus, the FDA reinforces the drug's established therapeutic role. This clarity helps ensure consistent understanding and application of the drug's approved uses in clinical practice, benefiting patient care by clearly defining the scope of treatment.
Source
The information regarding this label revision was sourced from the U.S. Food and Drug Administration (FDA). The updated label document, effective 2025-12-26, is available on dailymed.nlm.nih.gov.